Bioiberica guarantees that its sodium heparin will comply with the new parameters of the European Pharmacopeia
Bioiberica participated in two studies to establish the standard ranges of activity of Anti-factor Xa and anti-IIa of sodium heparin organized by EDQM, which will be included in the new revision of the monograph of the European Pharmacopoeia.
The results obtained with our product perfectly fit within the new established range. Therefore, we can guarantee that our sodium heparin will comply without any problem with the new parameters of the Pharmacopoeia.
Additionally Bioiberica wishes to inform its customers that the most relevant tests required for certification of the new EP have been performed with its sodium heparin and we can announce that we are prepared for the upcoming changes.
Related News
A crucial initiative to prevent shortages of critical medicines in the European Union.
The 28th Symposium on Glycosaminoglycans, an internationally renowned scientific event focusing on glycosaminoglycans, will be sponsored by
- Bioiberica produces 20% of the world's Heparin API.
- Heparin saves around a hundred million lives every year.
- One out of every 5 doses of heparin administered in the world comes from Bioiberica.